Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318901 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
A Phase 1 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02318901: Clinical Trial Phase 1 study, sponsored by Western Regional Medical Center.
NCT02318901 is a Phase 1 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02318901, a Phase 1 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine phase II arm will be for patients with HER2 overexpressing MBC. There will be two phase II cohorts for pembro plus cetuximab: one cohort will be for patients with HNSCC, the other cohort will be for patients with K-ras, B-raf, N-ras wildtype metastatic CRC.
Primary Outcome
PI left site. Study was prematurely terminated. No additional study items were conducted including, data collection, results or statistical analysis completed.
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Cetuximab
- DRUG ado-trastuzumab emtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
Why NCT02318901 stopped before completion
NCT02318901 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT02318901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02318901 about?
NCT02318901 is a clinical study titled "Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer". There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing metastatic breast cancer (MBC). The pembro plus ado-trastuzumab emtansine phase...
What is the current status of trial NCT02318901?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-10. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02318901?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Cetuximab (DRUG), ado-trastuzumab emtansine (DRUG).
Who is sponsoring clinical trial NCT02318901?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02318901's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia